01—Abstract
Summary
Summary of the 8-K filed June 5, 2026. Cited figures are marked; the original filing is the authoritative source.
On June 5, 2026, Natera, Inc. (NTRA) filed a Form 8-K under Item 5.02 reporting a board change.
Effective June 2, 2026, the Board of Directors increased the size of the full Board from eleven to twelve members and appointed Thomas Lynch as a member. Dr. Lynch was designated a Class I director with an initial term expiring at the 2028 annual meeting of stockholders, and the Board determined he is independent under the Securities Act and Nasdaq listing standards. The filing states that Dr. Lynch has been appointed to the Human Capital Committee.
He will receive cash and equity compensation consistent with the Company's other non-employee directors, as described in the Amended Compensation Program for Non-Employee Directors. His initial equity award vests as to one-third of the shares on each of June 26, 2027, 2028, and 2029. The Company also expects to enter into an Indemnification Agreement with him.
The filing states there is no arrangement or understanding under which Dr. Lynch was elected, no family relationships with any director or executive officer, and no material interest in any related-person transaction under Item 404(a) of Regulation S-K. The filing's exhibits are previously filed compensation, equity plan, and indemnification documents incorporated by reference, plus the XBRL cover page.
02—Key points
Key Highlights
- Board expanded from eleven to twelve members, effective June 2, 2026.
- Thomas Lynch appointed as a Class I director with an initial term expiring at the 2028 annual meeting.
- Board determined Dr. Lynch is independent under Securities Act and Nasdaq listing standards.
- Dr. Lynch appointed to the Human Capital Committee of the Board.
- Initial equity award vests one-third each on June 26, 2027, 2028, and 2029.
- Company expects to enter into an Indemnification Agreement with Dr. Lynch.
- No related-person transactions or family relationships disclosed for Dr. Lynch.
03—Questions
Frequently Asked Questions
Who was appointed to Natera's Board of Directors?
Thomas Lynch, referred to in the filing as Dr. Lynch, was appointed to the Board effective June 2, 2026, as a Class I director.
How large is the Board after this change?
The Board increased the size of the full Board from eleven to twelve members.
What committee will Dr. Lynch serve on?
The Board appointed Dr. Lynch to the Human Capital Committee.
How will Dr. Lynch be compensated?
He will receive cash and equity compensation consistent with the Company's other non-employee directors, as described in the Amended Compensation Program for Non-Employee Directors. His initial equity award vests as to one-third of the shares on each of June 26, 2027, 2028, and 2029.
Is Dr. Lynch considered independent?
Yes. The Board determined that Dr. Lynch qualifies as an independent director under the Securities Act of 1933, as amended, and the Nasdaq Stock Market listing standards.
04—Continue